At first glance, CHAMPION-AF gives some redemption to LAA occluders after CLOSURE-AF, a smaller randomized trial that failed to show that LAA closure (using various devices) was non-inferior to NOAC ...
In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...
In a finding that may have implications for percutaneous left atrial appendage (LAA) occlusion devices, a single-center series suggests that removing or closing off the LAA during cardiac surgery for ...
DUBLIN--(BUSINESS WIRE)--The "Left Atrial Appendage (LAA) Closure Devices Market" report has been added to ResearchAndMarkets.com's offering. The global left atrial appendage (LAA) closure devices ...
Abbott Laboratories (NYSE:ABT) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 6, Abbott Laboratories (NYSE:ABT) released positive clinical trial results for its Amulet 360 ...
Percutaneous left atrial appendage (LAA) closure not only successfully prevents stroke in patients with nonvalvular atrial fibrillation (A-fib) but is cost effective compared with warfarin and the ...
Initial results from more than 800 atrial fibrillation patients presented at Transcatheter Cardiovascular Therapeutics 2016 indicate the AMPLATZER™ Amulet™ LAA Occluder is a safe alternative to ...
Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients who underwent catheter ablation for atrial fibrillation, those who had left ...
Medicare patients undergoing left atrial appendage (LAA) occlusion with the Watchman device in routine practice tended to be sicker than the trial populations, translating into higher mortality rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results